| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 03/31/2005 | WO2005028463A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005028441A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | WO2005028439A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027949A1 Turmeric-containing composition |
| 03/31/2005 | WO2005027948A1 Powdery composition for use as a laxative |
| 03/31/2005 | WO2005027932A1 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2004108133A3 Modulators of vr1 receptor |
| 03/31/2005 | WO2004037161A3 Cyclic prodrugs of pmea one of its analogues |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | WO2002042319A9 2-substituted estrogens as antiangiogenic agents |
| 03/31/2005 | US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/31/2005 | US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |
| 03/31/2005 | US20050070694 Antagonistic anti-htnfsf13b human antibodies |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease |
| 03/31/2005 | US20050070574 Novel compounds |
| 03/31/2005 | US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 03/31/2005 | US20050070566 Imidazoquinoline derivatives |
| 03/31/2005 | US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions |
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070549 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation |
| 03/31/2005 | US20050070525 Such as 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2- alpha ]benzimidazol-4(10H)-one |
| 03/31/2005 | US20050070494 Transforming growth factor-beta response element decoys and methods |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070485 Phenylalanine derivatives |
| 03/31/2005 | US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 03/31/2005 | US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference |
| 03/31/2005 | US20050070461 Means and methods for altering the motility of the gastrointestinal tract |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069583 Solid, digestable mixture of alginate, (bi)carbonate and polyol; gastrointestinal disorders |
| 03/31/2005 | US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies |
| 03/31/2005 | US20050069569 Osteocalcin; enzyme inhibitors; promote bone, teeth growth; administering Dna gene |
| 03/31/2005 | US20050069559 Lawsonia intracellularis vaccine |
| 03/31/2005 | US20050069547 Binding protein; therapy for bone tumors |
| 03/31/2005 | US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 03/31/2005 | US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems |
| 03/31/2005 | DE10341518A1 Pharmazeutischer Wirkstoff gegen Hepatitis Pharmaceutical drug for hepatitis |
| 03/31/2005 | DE10331202A1 Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms Use of whey permeate for the treatment of metabolic syndrome |
| 03/31/2005 | CA2539799A1 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same |
| 03/31/2005 | CA2539165A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | CA2539162A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | CA2538960A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | CA2538760A1 Human .beta.-defensin secretion promoter |
| 03/30/2005 | EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 03/30/2005 | EP1517988A2 Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure |
| 03/30/2005 | EP1517923A2 Compositions and methods for inhibiting microbial adhesion |
| 03/30/2005 | EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 03/30/2005 | EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists |
| 03/30/2005 | EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 03/30/2005 | EP1517894A1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 03/30/2005 | EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 03/30/2005 | EP1517882A1 Amide linker peroxisome proliferator activated receptor modulators |
| 03/30/2005 | EP1517699A1 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation |
| 03/30/2005 | EP1517690A1 Liquid dosage forms of non-enterically coated acid-labile drugs |
| 03/30/2005 | EP1517688A2 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
| 03/30/2005 | EP1407047A4 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 03/30/2005 | EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists |
| 03/30/2005 | EP1290952B1 Compositions for taking dietary fibers |
| 03/30/2005 | EP1224163B1 Use of carbonylamino derivatives against cns disorders |
| 03/30/2005 | EP1194429B1 Potassium channel openers |
| 03/30/2005 | EP1191926B1 New omeprazole and (s)-omeprazole formulation |
| 03/30/2005 | EP1091942B1 Potassium channel blocking agents |
| 03/30/2005 | EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 03/30/2005 | EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders |
| 03/30/2005 | CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles |
| 03/30/2005 | CN1602360A Methods of increasing endogenous erythropoietin (EPO) |
| 03/30/2005 | CN1602358A Recombinant fusion proteins and the trimers thereof |
| 03/30/2005 | CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 03/30/2005 | CN1602308A Thiophene derivatives used as antiviral agent against flavivirus infections |
| 03/30/2005 | CN1602307A Substituted 6h-dibenzo[c, h]chromenes as estrogenic agents |
| 03/30/2005 | CN1602292A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists |
| 03/30/2005 | CN1602199A Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 03/30/2005 | CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 03/30/2005 | CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution |
| 03/30/2005 | CN1600856A Method for constructing hybridoma cell line of heterogeneity of seereting human monoclonal antibody for anti hepatitis B |
| 03/30/2005 | CN1600369A Method for preparing targeting preparation of human monoclonal antibody crosslinking interferon for anti hepatitis b virus |
| 03/30/2005 | CN1600358A Combination of medication for curing hyperlipemia, arteriosclerosis, coronary heart disease and fatty liver |
| 03/30/2005 | CN1600355A Medication for treating chronic gastritis and preparation method |
| 03/30/2005 | CN1600346A Technique of producing injection of Chinese traditional medicine for curing hepatitis |
| 03/30/2005 | CN1600334A Dedicated Chinese traditional medicine for curing gastric disease |
| 03/30/2005 | CN1600325A Capsule |
| 03/30/2005 | CN1600316A Drop Pills of cucurbitacin medication and preparation method |
| 03/30/2005 | CN1195062C Non-antibiotics resistant shuttle plasmid expression carrier and its constructing method and uses |
| 03/30/2005 | CN1194986C Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof |
| 03/30/2005 | CN1194982C Structure of phenethyl alcohol glycoside compound and its use |
| 03/30/2005 | CN1194976C Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 03/30/2005 | CN1194761C Dissolvent specially for omepazole sodium injection |
| 03/30/2005 | CN1194758C Vaginal lactobacillus medicant |
| 03/30/2005 | CN1194757C Medical health oral liquid and its prepn |
| 03/30/2005 | CN1194755C Medicine for treating hepatitis B and its preparation method |
| 03/30/2005 | CN1194754C Oral liquid for invigorating infant spleen and intestine and production thereof |